Top

Published in:

01-03-2022 | Hyperparathyroidism | Review Article

Management of Primary Hyperparathyroidism

Author: Murad Lala

Published in: Indian Journal of Surgical Oncology | Issue 1/2022

Abstract

Primary hyperparathyroidism (PHPT) is the unregulated overproduction of parathyroid hormone (PTH) resulting in abnormal calcium homeostasis. The disease profile has evolved over the last century from symptomatic hyperparathyroidism to asymptomatic hyperparathyroidism. Primary hyperparathyroidism is a biochemical diagnosis. Parathyroidectomy is the only established cure for this disease. Every effort is made to localize the offending gland preoperaively with various imaging modalities. These localization studies along with intraoperative parathormone monitoring will direct the surgeon to either a focused parathyroidectomy or a four gland exploration. All symptomatic patients and asymptomatic patients who meet the criteria for surgery should undergo parathyroidectomy if no medical contraindications exist. Pharmacologic approaches are reserved for those patients unfit or unwilling to undergo surgery.

Tezelman S, Shen W, Shaver JK et al (1993) Double parathyroid adenomas. Clinical and biochemical characteristics before and after parathyroidectomy. Ann Surg 218(3):300–309. https://doi.org/10.1097/00000658-199309000-00009CrossRefPubMedPubMedCentral

Bilezikian JP, Silverberg SJ, Clinical practice (2004) Asymptomatic primary hyperparathyroidism. N Engl J Med 350(17):1746–1751. https://doi.org/10.1056/NEJMcp032200CrossRefPubMed

Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA (2015) Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010). Bone 73:1–7. https://doi.org/10.1016/j.bone.2014.12.003CrossRefPubMed

Yeh MW, Ituarte PH, Zhou HC et al (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98(3):1122–1129. https://doi.org/10.1210/jc.2012-4022CrossRefPubMedPubMedCentral

Raue F, Jacubeit T, Minne H, Herfarth C, Ziegler R (1989) Primärer Hyperparathyreoidismus--Anderung eines Krankheitsbildes [Primary hyperparathyroidism--changes in the disease picture]. Med Klin (Munich) 84(4):178–182

Yadav SK, Johri G, Bichoo RA, Jha CK, Kintu-Luwaga R, Mishra SK (2020) Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Arch Endocrinol Metab 64(2):105–110. https://doi.org/10.20945/2359-3997000000211CrossRefPubMed

Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J (1995) Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 80(1):254–257. https://doi.org/10.1210/jcem.80.1.7829622CrossRefPubMed

Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, Wm O'F, Bl R (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14(10):1700–1707. https://doi.org/10.1359/jbmr.1999.14.10.1700CrossRefPubMed

Vignali E, Viccica G, Diacinti D et al (2009) Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 94(7):2306–2312. https://doi.org/10.1210/jc.2008-2006CrossRefPubMedPubMedCentral

10.

Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89(11):5415–5422. https://doi.org/10.1210/jc.2004-0028CrossRefPubMed

11.

Ambrogini E, Cetani F, Cianferotti L et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92(8):3114–3121. https://doi.org/10.1210/jc.2007-0219CrossRefPubMed

12.

Sheldon DG, Lee FT, Neil NJ, Ryan JA Jr (2002) Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg 137(9):1022–1028. https://doi.org/10.1001/archsurg.137.9.1022CrossRefPubMed

13.

Carnaille B, Oudar C, Pattou F, Combemale F, Rocha J, Proye C (1998) Pancreatitis and primary hyperparathyroidism: forty cases. Aust N Z J Surg 68(2):117–119. https://doi.org/10.1111/j.1445-2197.1998.tb04719.xCrossRefPubMed

14.

Tassone F, Guarnieri A, Castellano E, Baffoni C, Attanasio R, Borretta G (2015) Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab 100(8):3069–3073. https://doi.org/10.1210/jc.2015-2132CrossRefPubMed

15.

Miller PD, Bilezikian JP (2002) Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res 17(Suppl 2):N98–N102PubMed

16.

Syed Z, Khan A (2000) Skeletal effects of primary hyperparathyroidism. Endocr Pract 6(5):385–388. https://doi.org/10.4158/EP.6.5.385CrossRefPubMed

17.

Harari A, Waring A, Fernandez-Ranvier G et al (2011) Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 96(12):3679–3686. https://doi.org/10.1210/jc.2011-1571CrossRefPubMed

18.

Tezelman S, Rodriguez JM, Shen W, Siperstein AE, Duh QY, Clark OH (1995) Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J Am Coll Surg 180(1):81–87PubMed

19.

Sharretts JM, Simonds WF (2010) Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 24(3):491–502. https://doi.org/10.1016/j.beem.2010.01.003CrossRefPubMedPubMedCentral

20.

Castellano E, Attanasio R, Gianotti L, Cesario F, Tassone F, Borretta G (2016) Forearm DXA increases the rate of patients with asymptomatic primary hyperparathyroidism meeting surgical criteria. J Clin Endocrinol Metab 101(7):2728–2732. https://doi.org/10.1210/jc.2016-1513CrossRefPubMed

21.

Stephen AE, Mannstadt M, Hodin RA (2017) Indications for surgical management of hyperparathyroidism: a review. JAMA Surg 152(9):878–882. https://doi.org/10.1001/jamasurg.2017.1721CrossRefPubMed

22.

Zanocco K, Angelos P, Sturgeon C (2006) Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 140(6):874–882. https://doi.org/10.1016/j.surg.2006.07.032CrossRefPubMed

23.

Zanocco KA, Wu JX, Yeh MW (2017) Parathyroidectomy for asymptomatic primary hyperparathyroidism: a revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery 161(1):16–24. https://doi.org/10.1016/j.surg.2016.06.062CrossRefPubMed

24.

Mannoh EA, Thomas G, Solórzano CC, Mahadevan-Jansen A (2017) Intraoperative assessment of parathyroid viability using laser speckle contrast imaging. Sci Rep 7(1):14798. https://doi.org/10.1038/s41598-017-14941-5CrossRefPubMedPubMedCentral

25.

Mittendorf EA, Merlino JI, McHenry CR (2004) Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg 70(2):114–120PubMed

26.

Ajmi S, Sfar R, Trimeche S, Ben Ali K, Nouira M (2010) Scintigraphic findings in hungry bone syndrome following parathyroidectomy. Rev Esp Med Nucl 29(2):81–83. https://doi.org/10.1016/j.remn.2009.10.003CrossRefPubMed

27.

Gough I (2006) Reoperative parathyroid surgery: the importance of ectopic location and multigland disease. ANZ J Surg 76(12):1048–1050. https://doi.org/10.1111/j.1445-2197.2006.03931.xCrossRefPubMed

28.

Richards ML, Thompson GB, Farley DR, Grant CS (2008) Reoperative parathyroidectomy in 228 patients during the era of minimal-access surgery and intraoperative parathyroid hormone monitoring. Am J Surg 196(6):937–943. https://doi.org/10.1016/j.amjsurg.2008.07.022CrossRefPubMed

29.

Patow CA, Norton JA, Brennan MF (1986) Vocal cord paralysis and reoperative parathyroidectomy. A prospective study. Ann Surg 203(3):282–285. https://doi.org/10.1097/00000658-198603000-00011CrossRefPubMedPubMedCentral

30.

Mariette C, Pellissier L, Combemale F, Quievreux JL, Carnaille B, Proye C (1998) Reoperation for persistent or recurrent primary hyperparathyroidism. Langenbeck's Arch Surg 383(2):174–179. https://doi.org/10.1007/s004230050113CrossRef

31.

Karakas E, Müller HH, Schlosshauer T, Rothmund M, Bartsch DK (2013) Reoperations for primary hyperparathyroidism--improvement of outcome over two decades. Langenbeck's Arch Surg 398(1):99–106. https://doi.org/10.1007/s00423-012-1004-yCrossRef

32.

Weber CJ, Sewell CW, McGarity WC (1994) Persistent and recurrent sporadic primary hyperparathyroidism: histopathology, complications, and results of reoperation. Surgery 116(6):991–998PubMed

33.

Marcocci C, Bollerslev J, Khan AA, Shoback DM (2014) Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 99(10):3607–3618. https://doi.org/10.1210/jc.2014-1417CrossRef

34.

Wilkins BJ, Lewis JS Jr (2009) Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol 3(2):140–149. https://doi.org/10.1007/s12105-009-0115-4CrossRefPubMedPubMedCentral

35.

Givi B, Shah JP (2010) Parathyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):498–507. https://doi.org/10.1016/j.clon.2010.04.007CrossRef

36.

Wynne AG, van Heerden J, Carney JA et al (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71(4):197–205CrossRef

37.

Schantz A, Castleman B, Parathyroid carcinoma (1973) A study of 70 cases. Cancer 31(3):600–605. https://doi.org/10.1002/1097-0142(197303)31:3<600::aid-cncr2820310316>3.0.co;2-0CrossRefPubMed

38.

Silva-Figueroa AM, Hess KR, Williams MD et al (2017) Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg S1072-7515(17)30179. https://doi.org/10.1016/j.jamcollsurg.2017.01.060

39.

Montenegro FL, Chammas MC, Juliano AG, Cernea CR, Cordeiro AC (2008) Ethanol injection under ultrasound guidance to palliate unresectable parathyroid carcinoma. Arq Bras Endocrinol Metabol 52(4):707–711. https://doi.org/10.1590/s0004-27302008000400019CrossRefPubMed

40.

Stratigis S, Stylianou K, Mamalaki E et al (2008) Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism. Clin Endocrinol 69(4):542–548. https://doi.org/10.1590/s0004-27302008000400019CrossRef

Title: Management of Primary Hyperparathyroidism
Author: Murad Lala
Publication date: 01-03-2022
Publisher: Springer India
Keywords: Hyperparathyroidism
Parathyroidectomy
Parathyroidectomy
Parathyroid Cancer
Hypercalcemia
Published in: Indian Journal of Surgical Oncology / Issue 1/2022
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-021-01319-3

At a glance: The STEP trials

Springer Medicine

Management of Primary Hyperparathyroidism

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Is Performance of Routine Central Compartment Neck Dissection in cN0 Papillary Thyroid Cancers Really Useful? 10-Year Prospective Observational Study

Factors Influencing Cervical Lymph Node Metastasis in Pediatric Differentiated Thyroid Cancers

Revision Thyroid Surgery

Laryngeal Nerves and Voice Change in Thyroid Surgery

Molecular Markers in the Diagnosis of Thyroid Cancer in Indeterminate Thyroid Nodules

Outcome of 18f-Fluorodeoxyglucose Positron Emission Tomography (PET)-Directed Resections in Differentiated Thyroid Carcinoma (DTC): Experience in a Developing Country